Medistem Announces Establishment of Medical Advisory Board by International Licensee ICM; Recognized Medical Experts to Guide Research and Therapeutic Applications of Medistem's Proprietary Stem Cell Technology.

SCOTTSDALE, Ariz. -- Medistem Laboratories, Inc. (OTCBB:MDSM) (FWB:S2U), committed to the ethical development of next-generation medical therapies from non-controversial adult stem cell sources, has announced that its international licensee, the Institute for Cellular Medicine (ICM) in Costa Rica has established a Medical Advisory Board to institute and manage the medical protocols used to perpetuate ICM's research and clinical operations.

The Medical Advisory Board's mission is to ensure that ICM adheres to the highest standards of scientific and clinical practice as it further develops Medistem's non-controversial adult stem cell-sourced therapeutics at ICM's state-of-the-art clinical facility in Costa Rica

Six respected medical and scientific professionals have been named to the Medical Advisory Board. The initial six appointees are recognized international experts in diverse fields of medicine who bring a comprehensive range of experience and knowledge to the Board.

"We are confident that these experienced medical professionals will provide important guidance in managing the protocols to further develop Medistem's proprietary stem cell therapeutics," said Neil Riordan, Ph.D., Medistem's CEO.

The initial members of the Medical Advisory Board include the following six scientists and physicians.

--Dr. Adolfo Afonso, M.D. - Anesthesiologist and interventional anesthesia specialist at the Hospital CIMA in San Jose, Costa Rica, where he is also currently director of pain management. Previously, a Clinical Fellow at the University of Miami's Jackson Memorial Medical Center in the Department of Anesthesia and Perioperative Medicine, in Miami, FL. Member of the Florida Society of Anesthesiologists, American Society of Regional Anesthesia and Pain Medicine and American Society of Anesthesiologists.

--Dr. Samuel Flikier, M.D. - Accomplished ear, nose and throat specialist, who has lived and worked in numerous international locations and served as a pioneering surgeon and medical administrator. Has served as Doctor Specialist Assistant in Otorynolaryngology at the Marcial Rodriguez Outpatient Clinic and Hospital in San Rafael of Alajuela, Costa Rica, from 1999-2004, and previously as medical director of the Hospital Clinic Mount Sinai, in Ciudad Quesada, as well as Coordinator of Ambulatory Surgery for the National Hospital of Children (Hospital of Nacional de Ninos).

--Dr. Eduardo Glenn, Ph.D. - Professor and specialist in cell biology, formerly on the Faculty of Microbiology at the Universidad de Costa Rica. Brings a diverse background that includes Director of the National Commission for Toxicology and Quality of Food and as Assessor for the National Laboratory for Food Control at the Instituto Nacional de Investigaciones for the Ministry of Health (Ministerio de Salud) in Costa Rica. He is the Director and Founder of Provida, the first cord blood bank in Central America.

--Dr. Ivan Kafarela, M.D. - Specialist in internal medicine who has served in a variety of medical positions in Costa Rica, including Physician for the Peace Corps, Internist and Assistant in Emergencies at the Hospital Rafael Angel Calderon Guardia (Social Security Hospital), and as Medical Director and President of private medical emergency transport company, "Emergencias Metro."

--Dr. Jorge Mora, M.D. - Board Certified reconstructive and plastic surgeon and member of the Association of Plastic and Reconstructive Surgeons in Costa Rica. He is widely published and has lectured internationally on a range of topics in aesthetic plastic surgery. He is also a member of the Worldwide Confederation of Plastic Surgery and International Confederation for Plastic, Reconstructive and Aesthetic Surgery.

--Dr. Fabio Solano, M.D. - Medical Director of ICM and a veteran surgeon who specialized in gastroenterology with over thirty years experience. He is a recognized specialist in innovative anti-aging therapies. Dr. Solano is a member of the American College for Advancement in Medicine, a non-profit medical society dedicated to educating physicians in complementary and alternative medicine, with special emphasis on preventive and nutritional medicine.

"A growing body of independent research continues to demonstrate the vast untapped therapeutic medical promise of adult stem cell technology, and ICM has been established to contribute to the fundamental science in this field," said Dr. Fabio Solano, Medical Director of ICM. "We will look to the Medical Advisory Board to provide the medical protocols ICM will use in our research and clinical programs."

The establishment of ICM's Medical Advisory Board follows Medistem's recently executed technology licensing and royalty agreement with the Institute for Cellular Medicine, which enables ICM to perform clinical programs to further develop Medistem's stem cell technologies and therapies. The agreement also enables ICM to treat patients on a fee-for-service basis at their laboratory and clinic facility in San Jose, Costa Rica. The Institute expects to commence full operations before the end of the second quarter, following receipt of all applicable government licenses.

About Medistem Laboratories, Inc.

Medistem Laboratories is an innovative biotechnology company committed to the creation and commercialization of advanced medical therapies based on non-controversial adult stem cells. Medistem's corporate mission is to transform these stem cells into valuable medical treatments. The Company intends to create these treatments from adult stem cells derived from muscle, bone marrow and fat of adult patients seeking treatment, as well as from full-term, healthy placentas and umbilical cords, but not the controversial embryonic or fetal stem cells that are the focus of ethical and moral debates in some communities. The Company's business strategy calls for the establishment of a series of clinics and laboratories around the world to deliver unprecedented, next-generation cell therapies to help millions of patients. Initial development and treatment focus will use proprietary technology and cells sourced from umbilical cords, fat, bone marrow, and muscle for advanced treatment of cerebral palsy, stroke, cardiovascular disease and orthopedic diseases, primarily for the international marketplace. Additional applications ultimately will be targeted to the treatment of neurological disorders such as Parkinson's, Alzheimer's and certain types of cancer. Medistem believes it may hold a substantial competitive edge in the worldwide emerging market for stem cell-sourced medical solutions, positioning it to become a leading global provider of stem cell treatments on a fee-for-service basis, while accumulating intellectual property based on clinical and laboratory findings. For more information, please visit http://www.trilogy-capital.com/tcp/medistem/. To read or download Medistem's Investor Fact Sheet, please visit http://www.trilogy-capital.com/tcp/medistem/factsheet.html. To obtain daily and historical Company stock quote data, and recent Company news releases, visit http://www.trilogy-capital.com/tcp/medistem/quote.html. Medistem is traded on the Frankfurt, Germany, stock exchange under the symbol S2U.

Cautionary Statement

This document does not constitute an offer to sell or a solicitation of an offer to buy any of our securities. This document contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements contained herein can be identified by the use of forward-looking terminology such as "believes," "expects," "may," "will," "should," or "anticipates," or the negative thereof or other variations thereon or comparable terminology, or by discussions of strategy that involve risks and uncertainties. We wish to caution the reader that these forward-looking statements that are not historical facts, are only predictions. No assurances can be given that the future results indicated, whether expressed or implied, will be achieved.